Kathryn S. Kolibaba

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman et al. · Journal of Clinical Oncology · 2012 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Blood · 2014 · 638 citations · Full text

Life Sciences, Immunology, Internal Medicine +3

First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study

Ian W. Flinn, Richard van der Jagt, Brad S. Kahl et al. · Journal of Clinical Oncology · 2019 · 307 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells

J. Tyler Thiesing, Sayuri Ohno-Jones, Kathryn S. Kolibaba et al. · Blood · 2000 · 281 citations

Medicine, Oncology, Pharmacology +8

Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells

J. Tyler Thiesing, Sayuri Ohno-Jones, Kathryn S. Kolibaba et al. · Blood · 2000 · 250 citations

Medicine, Oncology, Pharmacology +8